Andrew Seeber
0000-0003-3159-2582
Publication & Citation Trends
Publications
0 total
Abstract 7101: Discovery of first-in-class YTHDC1 small molecule inhibitors for the treatment of MYC-driven cancers
Cited by 0
Semantic Scholar
Abstract PR004: Targeting aberrant condensate formation in fusion-positive cancers with an integrated discovery platform
Cited by 0
Semantic Scholar
Abstract B124: YTHDC1 inhibition as a therapeutic strategy with potent preclinical activity alone and in combination with BCL-2 inhibitors
Cited by 0
Semantic Scholar
Abstract 1657: Microfluidics-based screening platform identifies a novel therapeutic approach to targeting EML4-ALK driven cancers
Cited by 0
Semantic Scholar
Selective Inhibition of the m6a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia
Cited by 1
Semantic Scholar
244 (PB232): Pharmacologic inhibition of YTHDC1 biomolecular condensates as a novel approach to targeting L-MYC driven small cell lung cancer
Cited by 0
Semantic Scholar
Research Topics
Genomics and Chromatin Dynamics
(26)
DNA Repair Mechanisms
(20)
DNA and Nucleic Acid Chemistry
(8)
RNA Research and Splicing
(8)
Fungal and yeast genetics research
(6)
Affiliations
University of Geneva
Harvard University
University of Basel
Harvard University Press
FORS – Swiss Centre of Expertise in the Social Sciences